Overview of Recombinant Human C8A Protein

Complement component 8 subunit alpha (C8A) is an essential constituent of the membrane attack complex (MAC), which is the terminal effector structure of the complement system responsible for lysing target cells, including bacteria and opsonized erythrocytes. The mature C8 molecule is a heterotrimer composed of three genetically distinct subunits: C8α (encoded by C8A), C8β, and C8γ. The C8α subunit plays a critical role in MAC assembly by interacting with C5b-7 and subsequently recruiting and polymerizing C9 to form the lytic pore.

Recombinant Human C8A Protein (SKU: rp365856), available from Aladdin Scientific, is produced using recombinant expression systems to ensure batch-to-batch consistency and high purity suitable for a range of immunological and biochemical research applications. Researchers studying innate immunity, complement deficiency disorders, and host-pathogen interactions will find this protein a valuable tool.

Reconstitution and Storage Protocol

Materials Required:

• Sterile deionized water or phosphate-buffered saline (PBS, pH 7.4)
• Low-protein-binding microcentrifuge tubes
• Ice or wet ice bucket

Reconstitution Steps:

1. Allow the lyophilized protein vial to equilibrate to room temperature for 10–15 minutes before opening to minimize condensation and protein aggregation.
2. Briefly centrifuge the vial (1,000 × g, 30 seconds) to collect the lyophilized material at the bottom.
3. Reconstitute the protein by adding the recommended volume of sterile PBS (pH 7.4) or deionized water to yield the desired stock concentration. Gently pipette to mix; do not vortex.
4. Allow the reconstituted solution to stand on ice for 5 minutes to ensure complete dissolution.
5. Aliquot into single-use volumes using low-protein-binding tubes to minimize repeated freeze-thaw cycles.

Storage Conditions:

• Short-term (up to 1 week): Store at 2–8°C.
• Long-term: Store at -20°C or preferably -80°C.
• Avoid repeated freeze-thaw cycles, as this can lead to protein denaturation and loss of biological activity.

Note: Specific reconstitution volumes and recommended stock concentrations should be confirmed against the lot-specific Certificate of Analysis (CoA) supplied with the product.

Recommended Assay Applications and Working Concentrations

Recombinant Human C8A Protein is suitable for a range of in vitro research applications. The following are general guidelines; optimal conditions should be determined empirically by the end user.

ELISA: C8A protein can be used as a standard antigen to develop or validate sandwich or indirect ELISA assays for quantifying C8A levels. Coat plates at 0.5–2 µg/mL in carbonate-bicarbonate coating buffer (pH 9.6) overnight at 4°C. Confirm linearity with serial dilutions.

Western Blot: Use C8A protein as a positive control. Load 50–200 ng per lane under reducing or non-reducing conditions as appropriate. The expected molecular weight of C8A is approximately 64 kDa; verify against the product CoA, as recombinant tag additions may alter apparent molecular weight.

Functional Complement Assays: C8A protein can be employed to reconstitute C8-depleted serum for hemolytic assays studying MAC-mediated lysis. Titrate the protein concentration to restore hemolytic activity in a dose-dependent manner.

Protein–Protein Interaction Studies: Recombinant C8A is suitable for pull-down assays, surface plasmon resonance (SPR), or co-immunoprecipitation experiments to study interactions with C8β, C8γ, C5b-7, and C9.

Disclaimer: Working concentrations and assay conditions listed above are general recommendations based on standard biochemical practice and should be experimentally validated for each specific assay system.

Quality Control and Handling Precautions

Purity and Identity Verification: Prior to use, consult the Certificate of Analysis (CoA) for purity assessment (typically determined by SDS-PAGE and/or HPLC) and endotoxin levels. High endotoxin content can confound complement and immune cell assays. Ensure endotoxin levels are acceptable for your experimental system (generally <1 EU/µg for cell-based assays).

Protein Integrity Check: Run a small aliquot on SDS-PAGE before use in critical experiments to verify molecular weight and the absence of significant degradation bands.

Carrier Protein Considerations: Some recombinant protein formulations contain BSA or other stabilizers. Confirm with the product CoA whether carrier proteins are present, as they may interfere with certain downstream applications such as mass spectrometry or protein interaction studies.

General Laboratory Safety: Handle recombinant proteins following standard laboratory biosafety procedures. Wear appropriate personal protective equipment (PPE) including gloves and lab coat. Although Recombinant Human C8A Protein is not classified as hazardous under standard laboratory use, consult the product Safety Data Sheet (SDS) for specific handling and disposal information.

Preventing Protein Loss: Pre-wet pipette tips and low-protein-binding tubes with diluted protein solution before use to minimize adsorption losses, particularly at low working concentrations.

Troubleshooting Common Issues

Issue: No or weak signal in ELISA or Western blot
Possible causes: protein inactivation due to improper storage or repeated freeze-thaw; incorrect antibody; insufficient antigen loading. Verify storage history, check antibody compatibility with recombinant C8A, and increase antigen loading concentration.

Issue: Protein precipitate observed after reconstitution
Possible causes: rapid addition of reconstitution buffer; vortexing; incorrect buffer pH. Reconstitute slowly, use gentle pipetting, and ensure buffer pH is 7.2–7.4. Centrifuge at low speed (500 × g, 5 min) to pellet aggregates and use the supernatant, noting that some protein may have been lost.

Issue: Higher-than-expected apparent molecular weight on SDS-PAGE
Possible causes: presence of affinity or epitope tags (e.g., His-tag, Fc-tag) added during recombinant production; glycosylation of the expressed protein. Confirm expected molecular weight from the CoA and account for any fusion tags or post-translational modifications.

Issue: Inconsistent functional activity in hemolytic assays
Possible causes: variability in C8-depleted serum; suboptimal protein concentration; temperature fluctuations during assay. Standardize C8-depleted serum source, perform assays at consistent temperatures (37°C), and titrate C8A concentration carefully.